Wall Street Zen Upgrades HCW Biologics (NASDAQ:HCWB) to “Hold”

HCW Biologics (NASDAQ:HCWB) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $30.00.

HCW Biologics Price Performance

NASDAQ HCWB opened at $1.10 on Friday. The stock’s 50-day moving average is $1.92 and its 200-day moving average is $4.16. HCW Biologics has a one year low of $1.09 and a one year high of $23.94. The firm has a market cap of $2.46 million, a P/E ratio of -0.04 and a beta of 2.31.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings data on Friday, August 14th. The company reported ($11.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%. The company had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.14 million.

HCW Biologics Company Profile

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.